世界卫生组织指南关于不孕症预防、诊断和治疗的推荐意见
世界卫生组织(WHO)按照WHO指南制定手册,由30名多学科成员组成的指南制定组(GDG)基于系统评价和GRADE方法,制定了40条推荐和6条良好实践声明,覆盖不孕症的预防、诊断和治疗;大多数推荐为条件性推荐,因相关证据缺乏或确定性低或极低。
要点
- WHO发布40条推荐和6条良好实践声明,覆盖不孕症预防、诊断和治疗。
- 大多数推荐为条件性推荐,因证据缺乏或确定性低或极低。
- 指南基于系统评价和GRADE方法制定,由30名成员GDG及30名外部评审组完成。
核心结论
- WHO制定40条推荐和6条良好实践声明,用于不孕症的预防、诊断和治疗。
- 基于现有证据,GDG未对男性使用抗氧化补充剂做出推荐或不推荐。
- 大多数推荐为条件性推荐,因相关证据缺乏或确定性低或极低。
- 指南以公平、科学和将生育保健纳入全民健康覆盖为核心,旨在支持各国提供高质量、公平和有效的医疗保健。
研究设计与样本
- 指南根据WHO指南制定手册制定,组建了包括临床医生、政策制定者、研究者、实施者和患者团体代表的多学科且地域多样的指南制定组(GDG,n=30)。
- 开展了新的系统评价或更新了现有系统评价,采用GRADE方法评估证据确定性并指导推荐意见的形成。
- 推荐意见由包括30名成员的外部评审组(ERG)评审,并由WHO批准。
主要发现
- 指南提出6条与不孕症一般管理相关的良好实践声明,包括选择检测、倾听个体和夫妇、选择治疗决策、临床随访和记录治疗结局。
- 预防方面,提供关于生育和不孕症信息的推荐(n=1),以及减少性传播感染(STIs;n=1)、生活方式因素(n=1)和烟草使用(n=1)所致不孕症风险的推荐。
- 诊断方面,提供女性排卵功能障碍(n=3)、输卵管疾病(n=1)或宫腔异常(n=5)所致不孕症的诊断推荐;男性精液检测重复时机推荐(n=2);不明原因不孕症诊断推荐(n=1)。
- 治疗方面,提供多囊卵巢综合征(n=6)、输卵管疾病(n=5)、子宫纵隔(n=1)、精索静脉曲张(n=4)和不明原因不孕症(n=6)的治疗推荐。
关键数值与推荐
- WHO共发布40条推荐和6条良好实践声明。
- 6条良好实践声明涉及不孕症一般管理:选择检测、倾听个体和夫妇、选择治疗决策、临床随访和记录治疗结局。
- 预防相关推荐:提供生育和不孕症信息(n=1)、减少性传播感染(STIs;n=1)、生活方式因素(n=1)和烟草使用(n=1)所致不孕症风险。
- 诊断相关推荐:女性排卵功能障碍(n=3)、输卵管疾病(n=1)、宫腔异常(n=5);男性精液检测重复时机(n=2);不明原因不孕症(n=1)。
- 治疗相关推荐:多囊卵巢综合征(n=6)、输卵管疾病(n=5)、子宫纵隔(n=1)、精索静脉曲张(n=4)、不明原因不孕症(n=6)。
临床怎么用
- 指南主要供卫生保健专业人员使用,同时也是政策制定者制定国家指南的重要来源。
- 指南可为国家指南提供信息,并为患者支持组织(包括倡导组织、资助和慈善机构、民间社会、专业学会和其他非政府组织)的工作提供信息。
- 基于现有证据,GDG未对男性使用抗氧化补充剂做出推荐或不推荐。
局限性
- 推荐未覆盖不孕症和生育保健的所有方面,但指南后续版本将扩大推荐范围。
- 大多数推荐为条件性推荐,因相关证据缺乏或确定性低或极低。
- 已识别关键研究空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the recommended prevention, diagnosis, and treatment of infertility among individuals and couples? SUMMARY ANSWER: The World Health Organization (WHO) made 40 recommendations and six good practice statements for the prevention, diagnosis, and treatment of infertility. WHAT IS KNOWN ALREADY: The field of sexual and reproductive health care, including family planning has progressed in the last several decades. Significant progress has also been made in the field of medically assisted reproduction. Globally, one in six people experience infertility in their lifetime. However, many countries do not include the prevention, diagnosis, and treatment of infertility in health policies, financing, and services, and many do not have national clinical guidelines for the prevention, diagnosis, and treatment of infertility. STUDY DESIGN, SIZE, DURATION: The guideline was developed according to the WHO handbook for guideline development. A Guideline Development Group (GDG) was assembled and included a multidisciplinary and regionally diverse set of clinicians, policymakers, researchers, implementers, and representatives of patient groups (n=30). The GDG prioritized key recommendation questions to address in the guideline. PARTICIPANTS/MATERIALS, SETTING, METHODS: New systematic reviews were conducted, or existing reviews updated, to inform the recommendations. The GRADE approach was used to assess the certainty of the evidence and to guide the formulation of recommendations. The GDG interpreted evidence and made judgments about the balance between benefits and harms (including patients' values) as well as costs, feasibility, acceptability, and equity. The recommendations were drafted, reviewed by an External Review Group (ERG) comprising 30 members, and approved by the WHO. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline makes good practice statements related to the general management of infertility (n = 6) including (i) selection of tests, (ii) listening to individuals and couples with infertility, (iii) choosing treatment decisions, (iv) clinical follow-up, and (v) documenting outcomes of treatment. In relation to prevention, it provides recommendations related to the provision of information about fertility and infertility (n = 1) and reduction of infertility risk from sexually transmitted infections (STIs; n = 1), lifestyle factors (n = 1), and tobacco use (n = 1). In terms of diagnosis, recommendations for diagnosing infertility caused by ovulatory dysfunction (n = 3), tubal disease (n = 1), or uterine cavity abnormalities (n = 5) among females are provided. For males, the guideline provides recommendations regarding when a semen test should be repeated (n = 2). Also included is a recommendation for diagnosing unexplained infertility (n = 1). Regarding treatment, the guideline provides recommendations related to the treatment of polycystic ovary syndrome (n = 6), tubal disease (n = 5), uterine septae (n = 1), varicocele (n = 4), and unexplained infertility (n = 6). Based on available evidence, the GDG did not make a recommendation for or against the use of antioxidant supplements in males. Most recommendations were conditional because relevant evidence was either absent, or of low or very low certainty. Critical research gaps were identified. LIMITATIONS, REASONS FOR CAUTION: The recommendations do not cover all aspects of infertility and fertility care, but subsequent editions of the guideline will expand the scope of recommendations. WIDER IMPLICATIONS OF THE FINDINGS: By centring equity, science, and the imperative to provide fertility care as part of universal health coverage, the guideline aims to support countries in delivering high-quality, equitable, and effective healthcare for all. Although the guideline is primarily intended for use by health care professionals, it is an important source for policymakers to inform national guidelines and to inform the work of professional patient support, including advocacy organizations, funding and philanthropic agencies, civil society, professional societies, and other nongovernmental organizations that provide social, financial, and technical support to reproductive health programmes. STUDY FUNDING/COMPETING INTEREST(S): This work received funding from the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored programme executed by the World Health Organization (WHO). Full details of declared interests of all named authors are shown in Supplementary Table S1, those for members of the GDG who are not named authors are shown in Supplementary Table S2 and those for members of the ERG are shown in Supplementary Table S3. TRIAL REGISTRATION NUMBER: N/A. DISCLAIMER: This manuscript reports a summary of recommendations from a WHO guideline. All reasonable precautions have been taken by WHO to verify the information contained in the guideline publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
引用
- Mburu G, Santesso N, Brignardello-Petersen R, et al. Recommendations from the WHO guideline for the prevention, diagnosis, and treatment of infertility†. Hum Reprod. 2026. PMID: 41312724. doi:10.1093/humrep/deaf212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。